BLMH

BLMH

Target · Cysteine peptidase

BLMH Bleomycin hydrolase · BH

BLMH (bleomycin hydrolase, also known as BH or BMH) is a cytoplasmic cysteine peptidase of the papain superfamily. It is best known for inactivating the glycopeptide anticancer drug bleomycin, although its normal physiological role is unknown. Browse Assay Genie's current range of BLMH research reagents below, or read on for the biology behind the target.

Cytoplasmic cysteine peptidaseInactivates bleomycinHighly conserved through evolution
455 aa
Protein length
~53 kDa
Molecular weight
17q11.2
Gene locus
EC 3.4.22.40
Enzyme class
Target information

What is BLMH (bleomycin hydrolase)?

BLMH catalyses the inactivation of bleomycin (BLM), a glycopeptide antitumour drug, by hydrolysing the carboxamide bond of its B-aminoalaninamide moiety. In doing so it protects both normal and malignant cells from bleomycin toxicity. Bleomycin is an essential component of combination chemotherapy regimens for cancer, which is why this enzyme is of interest in studies of drug response and resistance. Beyond this activity, the normal physiological role of BLMH is unknown, and the metabolic inactivation of bleomycin is the only known activity of the enzyme.

BLMH is a cytoplasmic cysteine peptidase and is also found in cytoplasmic granules. It belongs to the peptidase C1 family, within the HGNC gene groups for peptidase family C1 and cysteine endopeptidases. The protein contains the signature active site residues of the papain superfamily of cysteine proteases, and it is highly conserved through evolution. Orthologues of the human BLMH gene are annotated in mouse (Blmh) and rat (Blmh).

The enzyme is listed under EC 3.4.22.40 and is also referred to as BH or BMH in the literature. Because its endogenous function remains undefined, BLMH is studied both as a bleomycin-metabolising enzyme and as a conserved member of the papain-like peptidase family. Researchers working with the BLMH protein, the BLMH gene or BLMH antibody and ELISA-based detection approaches typically do so in the context of bleomycin metabolism and cysteine protease biology.

Cancer chemotherapy research

BLMH inactivates bleomycin, a component of combination chemotherapy, so it is studied in relation to protection of normal and malignant cells from drug toxicity.

Drug metabolism studies

The only known activity of BLMH is the metabolic inactivation of bleomycin by hydrolysis of its B-aminoalaninamide carboxamide bond.

Cysteine protease biology

BLMH carries the signature active site residues of the papain superfamily and belongs to peptidase family C1, making it a model for papain-like enzymes.

Evolutionary conservation

The enzyme is highly conserved through evolution, yet its normal physiological role is unknown, which keeps its function an open research question.

Background

BLMH frequently asked questions

What does BLMH do?

BLMH is a cytoplasmic cysteine peptidase that inactivates the antitumour glycopeptide bleomycin by hydrolysing the carboxamide bond of its B-aminoalaninamide moiety. This protects normal and malignant cells from bleomycin toxicity. Its normal physiological role is unknown.

What other names does BLMH go by?

BLMH stands for bleomycin hydrolase, and the protein is also called BH or BMH. The enzyme is classified as EC 3.4.22.40 and sits in the peptidase C1 family, within the HGNC groups for peptidase family C1 and cysteine endopeptidases.

Is BLMH conserved across species?

Yes. BLMH is described as highly conserved through evolution, and orthologues are annotated in mouse and rat, both named Blmh. Check the datasheet of any product for its validated reactivity.

Explore

Related targets

Other peptidase C1 family cysteine peptidases and papain-like enzymes with products at Assay Genie.

Gene and protein annotations from HGNC, NCBI Gene and UniProt Q13867; product specifications from Assay Genie datasheets.

BLMH Product listing